Kymera Therapeutics, Inc. (KYMR)
118.15
-2.08
(-1.73%)
USD |
NASDAQ |
Aug 28, 16:00
118.22
+0.08
(+0.06%)
After-Hours: 20:00
Kymera Therapeutics Cash from Operations (Quarterly) : -54.06M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -54.06M |
| March 31, 2026 | -88.84M |
| December 31, 2025 | -66.75M |
| September 30, 2025 | -27.11M |
| June 30, 2025 | -59.88M |
| March 31, 2025 | -79.15M |
| December 31, 2024 | -61.78M |
| September 30, 2024 | -50.19M |
| June 30, 2024 | -42.94M |
| March 31, 2024 | -39.59M |
| December 31, 2023 | 8.045M |
| September 30, 2023 | -31.65M |
| June 30, 2023 | -35.26M |
| March 31, 2023 | -43.97M |
| Date | Value |
|---|---|
| December 31, 2022 | -39.54M |
| September 30, 2022 | -34.27M |
| June 30, 2022 | -38.98M |
| March 31, 2022 | -40.30M |
| December 31, 2021 | -38.35M |
| September 30, 2021 | -37.26M |
| June 30, 2021 | -30.51M |
| March 31, 2021 | -22.82M |
| December 31, 2020 | -20.07M |
| September 30, 2020 | 131.67M |
| June 30, 2020 | -11.41M |
| March 31, 2020 | -12.06M |
| December 31, 2019 | -10.80M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.28M |
| Sarepta Therapeutics, Inc. | 197.07M |
| Anixa Biosciences, Inc. | -1.741M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 20.04M |
| Cash from Financing (Quarterly) | 14.42M |
| Free Cash Flow | -237.96M |
| Free Cash Flow Per Share (Quarterly) | -0.5555 |
| Free Cash Flow to Equity (Quarterly) | -52.63M |
| Free Cash Flow to Firm (Quarterly) | -54.46M |
| Free Cash Flow Yield | -2.16% |